{"nctId":"NCT00683618","briefTitle":"Compare the Efficacy of Rosuvastatin to Atorvastatin in High Risk Patients With Hypercholesterolemia","startDateStruct":{"date":"2008-05"},"conditions":["Hypercholesterolemia"],"count":934,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: Rosuvastatin"]},{"label":"2","type":"EXPERIMENTAL","interventionNames":["Drug: Rosuvastatin"]},{"label":"3","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Atorvastatin"]}],"interventions":[{"name":"Rosuvastatin","otherNames":["Crestor"]},{"name":"Atorvastatin","otherNames":["Lipitor"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Treated for or diagnosed hypercholesterolemia or have had a high risk with hypercholesterolemia\n* LDL-C between 3.36mmol/L and 6.5 mmol/L if not treated with statin or between 2.6mmol/L and 4.14 mmol/L\n* Fasting triglyceride less than 4.52mmol/L\n\nExclusion Criteria:\n\n* History of statin induced myopathy\n* Unstable or uncontrolled cardiovascular diseases\n* Familial dysbetalipoproteinemia","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) Concentration After 6 Weeks of Treatment Comparing Rosuvastatin 5mg With Atorvastatin 10mg","description":"Analyzed with analysis of covariance (ANCOVA) model with factors fitted for treatment, centre, risk factor, lipid concentration at baseline, treatment by centre and treatment by risk factor with a two-sided significance level of 0.025 on ITT population.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-41.70","spread":"2.62"},{"groupId":"OG001","value":"-38.67","spread":"2.64"}]}]}]},{"type":"PRIMARY","title":"Percentage Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) Concentration After 6 Weeks of Treatment Comparing Rosuvastatin 10mg With Atorvastatin 10mg","description":"Analyzed with analysis of covariance (ANCOVA) model with factors fitted for treatment, centre, risk factor, lipid concentration at baseline, treatment by centre and treatment by risk factor with a significance level of 0.025 on ITT population.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-46.28","spread":"2.62"},{"groupId":"OG001","value":"-38.67","spread":"2.64"}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) at Week 6","description":"Analyzed with analysis of covariance (ANCOVA) model with factors fitted for treatment, centre, risk factor, lipid concentration at baseline, treatment by centre and treatment by risk factor with a significance level of 0.05 on ITT population.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.63","spread":"2.29"},{"groupId":"OG001","value":"6.82","spread":"2.29"},{"groupId":"OG002","value":"3.64","spread":"2.31"}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in Total Cholesterol (TC ) at Week 6","description":"Analyzed with analysis of covariance (ANCOVA) model with factors fitted for treatment, centre, risk factor, lipid concentration at baseline, treatment by centre and treatment by risk factor with a significance level of 0.05 on ITT population.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-29.62","spread":"1.92"},{"groupId":"OG001","value":"-33.14","spread":"1.91"},{"groupId":"OG002","value":"-28.06","spread":"1.93"}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in Triglycerides (TG) at Week 6","description":"Analyzed with analysis of covariance (ANCOVA) model with factors fitted for treatment, centre, risk factor, lipid concentration at baseline, treatment by centre and treatment by risk factor with a significance level of 0.05 on ITT population.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-20.09","spread":"4.72"},{"groupId":"OG001","value":"-22.05","spread":"4.69"},{"groupId":"OG002","value":"-20.67","spread":"4.73"}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in Non High Density Lipoprotein-Cholesterol (nonHDL-C) at Week 6","description":"Analyzed with analysis of covariance (ANCOVA) model with factors fitted for treatment, centre, risk factor, lipid concentration at baseline, treatment by centre and treatment by risk factor with a significance level of 0.05 on ITT population.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-38.60","spread":"3.57"},{"groupId":"OG001","value":"-46.08","spread":"3.57"},{"groupId":"OG002","value":"-38.50","spread":"3.60"}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in Apolipoprotein B (ApoB) at Week 6","description":"Analyzed with analysis of covariance (ANCOVA) model with factors fitted for treatment, centre, risk factor, lipid concentration at baseline, treatment by centre and treatment by risk factor with a significance level of 0.05 on ITT population.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-36.55","spread":"2.40"},{"groupId":"OG001","value":"-41.21","spread":"2.40"},{"groupId":"OG002","value":"-34.67","spread":"2.41"}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in Apolipoprotein A-I (ApoA-I) at Week 6","description":"Analyzed with analysis of covariance (ANCOVA) model with factors fitted for treatment, centre, risk factor, lipid concentration at baseline, treatment by centre and treatment by risk factor with a significance level of 0.05 on ITT population.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.67","spread":"1.99"},{"groupId":"OG001","value":"4.25","spread":"1.98"},{"groupId":"OG002","value":"1.79","spread":"2.00"}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in Total Cholesterol/High Density Lipoprotein-Cholesterol (TC/HDL-C) at Week 6","description":"Analyzed with analysis of covariance (ANCOVA) model with factors fitted for treatment, centre, risk factor, lipid concentration at baseline, treatment by centre and treatment by risk factor with a significance level of 0.05 on ITT population.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-32.95","spread":"2.96"},{"groupId":"OG001","value":"-38.04","spread":"2.96"},{"groupId":"OG002","value":"-31.92","spread":"2.99"}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in Low Density Lipoprotein Cholesterol/High Density Lipoprotein Cholesterol (LDL-C/HDL-C) at Week 6","description":"Analyzed with analysis of covariance (ANCOVA) model with factors fitted for treatment, centre, risk factor, lipid concentration at baseline, treatment by centre and treatment by risk factor with a significance level of 0.05 on ITT population.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-44.07","spread":"3.17"},{"groupId":"OG001","value":"-50.27","spread":"3.16"},{"groupId":"OG002","value":"-41.04","spread":"3.19"}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in Non High Density Lipoprotein Cholesterol/High Density Lipoprotein Cholesterol (nonHDL-C/HDL-C) at Week 6","description":"Analyzed with analysis of covariance (ANCOVA) model with factors fitted for treatment, centre, risk factor, lipid concentration at baseline, treatment by centre and treatment by risk factor with a significance level of 0.05 on ITT population.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-41.79","spread":"11.54"},{"groupId":"OG001","value":"-56.63","spread":"11.52"},{"groupId":"OG002","value":"-48.33","spread":"11.64"}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in Apolipoprotein B/Apolipoprotein A I (ApoB/ApoA-I) at Week 6","description":"Analyzed with analysis of covariance (ANCOVA) model with factors fitted for treatment, centre, risk factor, lipid concentration at baseline, treatment by centre and treatment by risk factor with a significance level of 0.05 on ITT population.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-37.62","spread":"3.15"},{"groupId":"OG001","value":"-41.87","spread":"3.14"},{"groupId":"OG002","value":"-35.15","spread":"3.16"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Achieved ATP III Guideline (2001) Low Density Lipoprotein Cholesterol (LDL-C) Goal at Week 6","description":"The percentage of patients achieved LDL-C goal is done in ITT population.\n\nNational Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) guideline (2001) LDL-C goal:\n\nModerately high risk: 2+ risk factors (10-year risk 10%-20%): LDL-C goal \\< 3.36mmol/L(130mg/dL), non-HDL-C goal \\< 4.14mmol/L (160mg/dL) ; High risk: Coronary Heart Disease (CHD) or CHD risk equivalents (10-year risk \\>20%): LDL-C goal\\< 2.60mmol/L (100mg/dL), non-HDL-C goal \\< 3.36mmol/L (130mg/dL)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61.0","spread":null},{"groupId":"OG001","value":"79.1","spread":null},{"groupId":"OG002","value":"58.3","spread":null}]}]}]},{"type":"SECONDARY","title":"6 weeksPercentage of Patients Achieved ATP III Guideline (2001) Non High Density Lipoprotein-Cholesterol (nonHDL-C) Goal at Week 6","description":"The percentage of patients achieved LDL-C goal is done in ITT population.\n\nNational Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) guideline (2001) LDL-C goal:\n\nModerately high risk: 2+ risk factors (10-year risk 10%-20%): LDL-C goal \\< 3.36mmol/L(130mg/dL); non-HDL-C goal \\< 4.14mmol/L (160mg/dL) ; High risk: Coronary Heart Disease (CHD) or CHD risk equivalents (10-year risk \\>20%): LDL-C goal\\< 2.60mmol/L (100mg/dL),non-HDL-C goal \\< 3.36mmol/L (130mg/dL)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.9","spread":null},{"groupId":"OG001","value":"78.4","spread":null},{"groupId":"OG002","value":"60.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Achieved National Cholesterol Education Program Adult Treatment Panel (NCEP ATP) III Guideline (2001) Low Density Lipoprotein-Cholesterol (LDL-C) Goal After Titration","description":"The percentage of patients achieved LDL-C goal is done in ITT population.\n\nNational Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) guideline (2001) LDL-C goal:\n\nModerately high risk: 2+ risk factors (10-year risk 10%-20%): LDL-C goal \\< 3.36mmol/L(130mg/dL), non-HDL-C goal \\< 4.14mmol/L (160mg/dL) ; High risk: Coronary Heart Disease (CHD) or CHD risk equivalents (10-year risk \\>20%): LDL-C goal\\< 2.60mmol/L (100mg/dL), non-HDL-C goal \\< 3.36mmol/L (130mg/dL)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.2","spread":null},{"groupId":"OG001","value":"47.6","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":145},"commonTop":["Blood Creatine Phosphokinase Increased","Alanine Aminotransferase","Myalgia"]}}}